These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21083245)

  • 21. Drug discovery projects. Preface.
    Lawton G; Witty DR
    Prog Med Chem; 2011; 50():v-vi. PubMed ID: 21476319
    [No Abstract]   [Full Text] [Related]  

  • 22. Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.
    Prideaux B; Lenaerts A; Dartois V
    Curr Opin Chem Biol; 2018 Jun; 44():93-100. PubMed ID: 29957376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicology Strategies for Drug Discovery - Present and Future: Introduction.
    Humphreys WG; Will Y; Guengerich FP
    Chem Res Toxicol; 2016 Apr; 29(4):437. PubMed ID: 27087588
    [No Abstract]   [Full Text] [Related]  

  • 25. Microdosing drugs: a versatile technique to detect and assess drug-drug interactions.
    Foerster KI; Burhenne J
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):447-448. PubMed ID: 32336179
    [No Abstract]   [Full Text] [Related]  

  • 26. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in Mass Spectrometry Within Drug Discovery.
    Wingfield J; Wilson ID
    J Biomol Screen; 2016 Feb; 21(2):109-10. PubMed ID: 26773070
    [No Abstract]   [Full Text] [Related]  

  • 28. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technologies and strategies to characterize and quantitate metabolites in drug discovery and development.
    Ravindran S; Jadhav A; Surve P; Lonsane G; Honrao P; Nanda B
    Biomed Chromatogr; 2014 Nov; 28(11):1547-53. PubMed ID: 25175001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failed Pediatric Drug Development Trials.
    Momper JD; Mulugeta Y; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ask the experts: computational chemistry.
    Matta CF; Hutter MC
    Future Med Chem; 2018 Jul; 10(13):1521-1524. PubMed ID: 29992825
    [No Abstract]   [Full Text] [Related]  

  • 32. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of modeling and simulation: myth or fact?
    Allerheiligen SR
    Clin Pharmacol Ther; 2014 Oct; 96(4):413-5. PubMed ID: 25236663
    [No Abstract]   [Full Text] [Related]  

  • 34. Overview of drug discovery and development.
    Ator MA; Mallamo JP; Williams M
    Curr Protoc Pharmacol; 2006 Dec; Chapter 9():Unit9.9. PubMed ID: 22294181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical validation of accelerator mass spectrometry for pharmaceutical development.
    Keck BD; Ognibene T; Vogel JS
    Bioanalysis; 2010 Mar; 2(3):469-85. PubMed ID: 21083256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addressing toxicity risk when designing and selecting compounds in early drug discovery.
    Segall MD; Barber C
    Drug Discov Today; 2014 May; 19(5):688-93. PubMed ID: 24451294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tiered approach to address regulatory drug metabolite-related issues in drug development.
    Ma S; Chowdhury SK
    Bioanalysis; 2014 Mar; 6(5):587-90. PubMed ID: 24620798
    [No Abstract]   [Full Text] [Related]  

  • 38. Capillary electrophoresis-mass spectrometry in metabolomics: the potential for driving drug discovery and development.
    Wang X; Li K; Adams E; Van Schepdael A
    Curr Drug Metab; 2013 Sep; 14(7):807-13. PubMed ID: 23937174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometry imaging for drug distribution studies.
    Prideaux B; Stoeckli M
    J Proteomics; 2012 Aug; 75(16):4999-5013. PubMed ID: 22842290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making Every Subject Count: A Case Study of Drug Development Path for Medication in a Pediatric Rare Disease.
    Bhattacharya I; Manukyan Z; Chan P; Harnisch L; Heatherington A
    Clin Pharmacol Ther; 2016 Oct; 100(4):330-2. PubMed ID: 27351288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.